@dromar.eth

New Masala study out. 891 South Asian Americans. Mean BMI was 26. Not a single one would get flagged in a standard checkup. Yet 73.5% had dyslipidemia. 40.3% had hypertension. 25.3% had diabetes. Reminder MASALA cohort: the largest study of South Asian Americans they mapped adipokine profiles to cardiometabolic outcomes within our population. What they found: → Higher adiponectin = 35% lower odds of dyslipidemia (OR 0.65) → In women, each SD increase in adiponectin = 46% lower odds of diabetes (OR 0.54) → In men? The association was flat. OR 1.01. Nothing. → Leptin: the hormone everyone measures...predicted nothing after adjustment → The Adiponectin-Resistin Index showed 83% higher odds of diabetes in women The sex difference was statistically significant (p = 0.02). THis was the interesting bit. Here's why this matters: We've been building a mechanistic framework at Zinda for why South Asians develop metabolic disease at lower BMIs. But a framework without clinical data is just a story. This study gives the framework numbers. Adiponectin, the hormone most doctors never measure, is directly associated with protection against the diseases killing South Asians at the highest rates. And the sex split tells us something crucial about precision medicine: the same deficit, the same ancestry, but different clinical expression depending on whether you're a South Asian man or woman. One size doesn't fit all. Even within our own community. The messiest finding? Higher resistin was associated with lower diabetes risk in men (OR 0.63). The authors flag this as largely unreported elsewhere. It complicates the tidy narrative, and that's exactly why this study matters. Real data is messy. Mechanistic reasoning alone isn't enough. Full deep dive on the Substack: https://open.substack.com/pub/grasshoppermed/p/chai-shots008-the-missing-brake-has?r=1fp8g&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

0 reply

0 recast

3 reactions